argenx (ARGX) to Release Earnings on Thursday

argenx (NASDAQ:ARGX) is set to post its quarterly earnings results before the market opens on Thursday, May 9th. Analysts expect argenx to post earnings of ($0.71) per share for the quarter.

argenx (NASDAQ:ARGX) last issued its earnings results on Thursday, February 29th. The company reported ($1.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.45). argenx had a negative return on equity of 16.97% and a negative net margin of 23.26%. The business had revenue of $417.84 million for the quarter, compared to the consensus estimate of $378.60 million. During the same quarter in the previous year, the company earned ($0.70) earnings per share. On average, analysts expect argenx to post $-2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

argenx Stock Performance

argenx stock traded up $4.28 during midday trading on Thursday, hitting $387.62. 36,793 shares of the company’s stock were exchanged, compared to its average volume of 310,195. argenx has a 12 month low of $327.73 and a 12 month high of $550.76. The company has a market cap of $23.04 billion, a PE ratio of -74.75 and a beta of 0.67. The firm has a 50-day moving average of $384.46 and a two-hundred day moving average of $413.84.

Analyst Ratings Changes

A number of analysts have recently weighed in on ARGX shares. HC Wainwright restated a “buy” rating and issued a $451.00 price target on shares of argenx in a report on Thursday, April 18th. Robert W. Baird lowered their price target on shares of argenx from $505.00 to $490.00 and set an “outperform” rating on the stock in a report on Friday, March 1st. JMP Securities restated a “market outperform” rating and issued a $471.00 price target on shares of argenx in a report on Friday, March 22nd. Wedbush restated an “outperform” rating and issued a $521.00 price target on shares of argenx in a report on Thursday, April 18th. Finally, Scotiabank raised their price target on shares of argenx from $402.00 to $408.00 and gave the company a “sector perform” rating in a report on Tuesday, March 26th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $528.16.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.